Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: New Zealand,Spain,Taiwan, Province of China,Thailand,Portugal,Italy,Finland,United States,Czech Republic - Le promoteur: nct
nct
MAJ Il y a 5 ans
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma. The aim of the study is to investigate the effect of roflumilast taken orally together with low dose inhaled corticosteroids on lung function. Roflumilast will be administered at one dose level once daily together with inhaled corticosteroids at one dose level twice daily. The study duration consists of a baseline period (2 to 6 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.
Pays
Austria
,
Croatia
,
Czech Republic
,
Finland
,
France
,
Greece
,
Hungary
,
India
,
Ireland
,
Italy
,
New Zealand
,
Norway
,
Pakistan
,
Philippines
,
Poland
,
Portugal
,
Russian Federation
,
Singapore
,
South Africa
,
Spain
,
Taiwan, Province of China
,
Thailand
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1